AB0309 FRACTURE RISK FOLLOWING DENOSUMAB DISCONTINUATION IN THE ONCOLOGIC POPULATION: INCIDENCE AND...
AB0309 FRACTURE RISK FOLLOWING DENOSUMAB DISCONTINUATION IN THE ONCOLOGIC POPULATION: INCIDENCE AND RISK FACTORS
About this item
Full title
Author / Creator
Amigues, C. , Trojani, M.C. , Roux, C. , Caroline, B. , Cabane, L. and Breuil, V.
Publisher
Kidlington: Elsevier Limited
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: Elsevier Limited
Subjects
More information
Scope and Contents
Contents
Background:Denosumab (DENO) reduces Skeletal-related events (SRE) from bone metastases in solid cancers. In the treatment of postmenopausal osteoporosis, interrupting DENO is associated with a “fracture rebound,” which can be limited by switching to a bisphosphonate (BP). However, there is no available data on the fracture risk following DENO disco...
Alternative Titles
Full title
AB0309 FRACTURE RISK FOLLOWING DENOSUMAB DISCONTINUATION IN THE ONCOLOGIC POPULATION: INCIDENCE AND RISK FACTORS
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_3100849477
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3100849477
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2024-eular.916
